172 related articles for article (PubMed ID: 19490420)
1. Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study.
Tandon P; Moncrief K; Madsen K; Arrieta MC; Owen RJ; Bain VG; Wong WW; Ma MM
Liver Int; 2009 Aug; 29(7):1110-5. PubMed ID: 19490420
[TBL] [Abstract][Full Text] [Related]
2. VSL#3 ® probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis.
Jayakumar S; Carbonneau M; Hotte N; Befus AD; St Laurent C; Owen R; McCarthy M; Madsen K; Bailey RJ; Ma M; Bain V; Rioux K; Tandon P
Liver Int; 2013 Nov; 33(10):1470-7. PubMed ID: 23968203
[TBL] [Abstract][Full Text] [Related]
3. Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial.
Gupta N; Kumar A; Sharma P; Garg V; Sharma BC; Sarin SK
Liver Int; 2013 Sep; 33(8):1148-57. PubMed ID: 23601333
[TBL] [Abstract][Full Text] [Related]
4. Haemodynamic derangement in human immunodeficiency virus-infected patients with hepatitis C virus-related cirrhosis: the role of bacterial translocation.
Montes-de-Oca M; Blanco MJ; Marquez M; Soto MJ; Fernandez-Gutiérrez C; Rodriguez-Ramos C; Giron-Gonzalez JA
Liver Int; 2011 Jul; 31(6):850-8. PubMed ID: 21645216
[TBL] [Abstract][Full Text] [Related]
5. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.
Afdhal N; Everson GT; Calleja JL; McCaughan GW; Bosch J; Brainard DM; McHutchison JG; De-Oertel S; An D; Charlton M; Reddy KR; Asselah T; Gane E; Curry MP; Forns X
J Viral Hepat; 2017 Oct; 24(10):823-831. PubMed ID: 28295923
[TBL] [Abstract][Full Text] [Related]
6. Bacterial translocation in HIV-infected patients with HCV cirrhosis: implication in hemodynamic alterations and mortality.
de Oca Arjona MM; Marquez M; Soto MJ; Rodriguez-Ramos C; Terron A; Vergara A; Arizcorreta A; Fernandez-Gutierrez C; Giron-González JA
J Acquir Immune Defic Syndr; 2011 Apr; 56(5):420-7. PubMed ID: 21266909
[TBL] [Abstract][Full Text] [Related]
7. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
[TBL] [Abstract][Full Text] [Related]
8. Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis.
Fernández J; Clària J; Amorós A; Aguilar F; Castro M; Casulleras M; Acevedo J; Duran-Güell M; Nuñez L; Costa M; Torres M; Horrillo R; Ruiz-Del-Árbol L; Villanueva C; Prado V; Arteaga M; Trebicka J; Angeli P; Merli M; Alessandria C; Aagaard NK; Soriano G; Durand F; Gerbes A; Gustot T; Welzel TM; Salerno F; Bañares R; Vargas V; Albillos A; Silva A; Morales-Ruiz M; Carlos García-Pagán J; Pavesi M; Jalan R; Bernardi M; Moreau R; Páez A; Arroyo V
Gastroenterology; 2019 Jul; 157(1):149-162. PubMed ID: 30905652
[TBL] [Abstract][Full Text] [Related]
9. Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study.
Lim YL; Kim MY; Jang YO; Baik SK; Kwon SO
Gut Liver; 2017 Sep; 11(5):702-710. PubMed ID: 28651304
[TBL] [Abstract][Full Text] [Related]
10. Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response.
Simbrunner B; Caparrós E; Neuwirth T; Schwabl P; Königshofer P; Bauer D; Marculescu R; Trauner M; Scheiner B; Stary G; Mandorfer M; Reiberger T; Francés R
Hepatol Int; 2023 Aug; 17(4):1045-1056. PubMed ID: 36881247
[TBL] [Abstract][Full Text] [Related]
11. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
Arab JP; Martin-Mateos RM; Shah VH
Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis.
Genesca J; Gonzalez A; Segura R; Catalan R; Marti R; Varela E; Cadelina G; Martinez M; Lopez-Talavera JC; Esteban R; Groszmann RJ; Guardia J
Am J Gastroenterol; 1999 Jan; 94(1):169-77. PubMed ID: 9934750
[TBL] [Abstract][Full Text] [Related]
13. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
Ripoll C; Groszmann R; Garcia-Tsao G; Grace N; Burroughs A; Planas R; Escorsell A; Garcia-Pagan JC; Makuch R; Patch D; Matloff DS; Bosch J;
Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
[TBL] [Abstract][Full Text] [Related]
14. Non-invasive aspartate aminotransferase to platelet ratio index correlates well with invasive hepatic venous pressure gradient in cirrhosis.
Kirnake V; Arora A; Sharma P; Goyal M; Chawlani R; Toshniwal J; Kumar A
Indian J Gastroenterol; 2018 Jul; 37(4):335-341. PubMed ID: 30178093
[TBL] [Abstract][Full Text] [Related]
15. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study.
Pinter M; Sieghart W; Reiberger T; Rohr-Udilova N; Ferlitsch A; Peck-Radosavljevic M
Aliment Pharmacol Ther; 2012 Jan; 35(1):83-91. PubMed ID: 22032637
[TBL] [Abstract][Full Text] [Related]
16. Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites.
Rincón D; Vaquero J; Hernando A; Galindo E; Ripoll C; Puerto M; Salcedo M; Francés R; Matilla A; Catalina MV; Clemente G; Such J; Bañares R
Liver Int; 2014 Nov; 34(10):1504-12. PubMed ID: 24661740
[TBL] [Abstract][Full Text] [Related]
17. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.
Reiberger T; Ferlitsch A; Payer BA; Mandorfer M; Heinisch BB; Hayden H; Lammert F; Trauner M; Peck-Radosavljevic M; Vogelsang H;
J Hepatol; 2013 May; 58(5):911-21. PubMed ID: 23262249
[TBL] [Abstract][Full Text] [Related]
18. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
[TBL] [Abstract][Full Text] [Related]
19. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.
Bishnu S; Ahammed SM; Sarkar A; Hembram J; Chatterjee S; Das K; Dhali GK; Chowdhury A; Das K
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):54-59. PubMed ID: 29099421
[TBL] [Abstract][Full Text] [Related]
20. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
